+1-888-308-5802     
News Contact Us

Calithera begins clinical study of drug combination in cancer patients

Author : Saif Ali Bepari | Published Date : 2019-07-04 

Calithera Biosciences, a clinical-stage biotech company focused on developing small molecule drugs to treat cancer and life-threatening diseases, recently announced that it has treated the first patient in an open-label Phase 1/2 clinical trial of Glutaminase inhibitor telaglenastat combined with Pfizer’s CDK 4/6 inhibitor palbociclib, alternatively called Ibrance.

The study will be evaluating the anti-tumor activity and safety of telaglenastat-pluspalbociclib combination in patients with KRAS-mutated non-small cell lung cancer (NSCLC) and KRAS-mutated colorectal cancer (CRC).

President and chief executive officer at Calithera, Susan Molineaux said that preclinical data indicate palbociclib and telaglenastat perform synergistically in KRAS-mutated tumors, which will offer a different approach to the challenges that are associated with the treatment of KRAS-mutated cancers.

The company is looking forward to launching a second trial with Pfizer and expect that the combination of telaglenastat and palbociclib will fill a major treatment gap for both the medical professionals and patients, Molineaux  mentioned.

Apparently, telaglenastat is designed in a way that it is capable of blocking glutamine consumption in tumor cells. Telaglenastat reportedly showed synergistic antitumor effects in a preclinical KRAS-mutated cancer models. It was used with CDK4/6 inhibitors like palbociclib, that enhanced blocking of cancer cell proliferation and cell cycle arrest.

According to reliable sources, the Phase 1/2 clinical trial will be evaluating the anti-tumor activity and the safety of the combination of telaglenastat and palbociclib in patients suffering with locally advanced KRAS-mutated NSCLC or KRAS-mutated CRC, both of which are intolerant to standard therapies and refractory.

For the record, Calithera has initiated a second trial that is part of the Pfizer’s current clinical trial agreement. The first trial is reportedly testing the combination of telaglenastat with PARP inhibitor talazaporib. It is underway in patients with triple negative breast cancer ( TNBC), CRC and renal cell carcinoma (RCC). The first trial begun enrolling patients in March and Pfizer will provide talazoparib and palbociclib along with monetary support as per the agreement.

Source Credit- http://ir.calithera.com/news-releases/news-release-details/calithera-biosciences-initiates-phase-12-trial-telaglenastat-0?field_nir_news_date_value%5bmin%5d=

About Author

Saif Ali Bepari

Saif Ali Bepari

A qualified Computer Science graduate, Saif Ali Bepari, armed with more of an inclination toward writing than coding, commenced his journey in the content industry as a freelancer. Currently penning down content for fractovia.org and a couple of other portals, Saif has also tinkered with creative writing, technical writing, blog writing, and copywriting. He can be contacted at- [email protected] | https://twitter.com/Saif_B17

Related News

Amazon extends anti-counterfeit Transparency program beyond U.S.

Published Date: 2019-07-12         Author: Saif Ali Bepari

Amazon has recently announced that it is expanding the Transparency program, an initiative to address counterfeit problems in e-commerce, to India, Canada and Europe. Transparency is aimed at serializing products with a T-shaped QR type code to help in the identification of a counterfeit item. Vi... Read More

ABB to build collaborative robotic solutions for healthcare automation

Published Date: 2019-07-11         Author: Saif Ali Bepari

ABB has recently announced that it will launch collaborative robots for medical laboratories, with the opening of a new healthcare hub at Houston-based Texas Medical Center (TMC) facility. Apparently, the innovation center will be the firm’s first dedicated healthcare research center and is se... Read More

Wahoo buys The Sufferfest to expand home training systems portfolio

Published Date: 2019-07-09         Author: Saif Ali Bepari

Reports confirm that Wahoo, a fitness-tech company, has announced the acquisition of The Sufferfest, a leading home training brand established by David McQuillen in 2008. Apparently, Wahoo, a connected fitness device leader, is known for the Kickr turbo trainers, the Elemnt computer family and Ti... Read More

© 2019 Fractovia. All Rights Reserved